ライフサイエンスコーパス: adrenomyeloneuropathy

1 dults as a progressive spinal cord syndrome (adrenomyeloneuropathy).

2 metabolism, such as adrenoleukodystrophy and adrenomyeloneuropathy.

3 ave a poor prognosis owing to development of adrenomyeloneuropathy.

4 ted ABCD1 delivery to the brain in mice with adrenomyeloneuropathy.

5 gic pathway may contribute to dysfunction in adrenomyeloneuropathy.

6 le of neuronal ABCD1 in mice and humans with adrenomyeloneuropathy.

7 arkers of disease progression in adults with adrenomyeloneuropathy.

8 The most common manifestation is adrenomyeloneuropathy, a hereditary spastic paraplegia o

9 hy has two distinct neurological phenotypes: adrenomyeloneuropathy, a non-inflammatory axonopathy mos

10 had established severe motor disability from adrenomyeloneuropathy affecting only the spinal cord and

11 hich manifests as the spinal cord axonopathy adrenomyeloneuropathy (AMN) in nearly all males survivin

12 "Pure" adrenomyeloneuropathy (AMN) is the noninflammatory myelo

13 Among 68 adrenomyeloneuropathy (AMN) patients initially without c

14 ly variable, ranging from slowly progressive adrenomyeloneuropathy (AMN) to life-threatening inflamma

15 ween ALD phenotypes in patients with cALD or adrenomyeloneuropathy (AMN), heterozygote female carrier

16 imaging (MRI) were evaluated in 84 men with adrenomyeloneuropathy (AMN).

17 ing from progressive spinal cord axonopathy [adrenomyeloneuropathy (AMN)] to severe demyelination and

18 a cross-sectional study on 13 patients with adrenomyeloneuropathy and 12 age-matched healthy control

19 Asymptomatic, adrenomyeloneuropathy and female heterozygote patients h

20 ionally, a large proportion of patients with adrenomyeloneuropathy develop life-threatening progressi

21 Adrenomyeloneuropathy is the late-onset form of X-linked

22 2), neoplasia (n = 2), genetically confirmed adrenomyeloneuropathy (n = 1), and other conditions (n =

23 , a life-threatening event for patients with adrenomyeloneuropathy, occurred only in patients in the

24 In conclusion, in adrenomyeloneuropathy patients quantitative magnetic res

25 enoleukodystrophy mouse model often have the adrenomyeloneuropathy phenotype.

26 hological features in a mouse model of human Adrenomyeloneuropathy, preceding disease-onset by one ye

27 l changes that can characterize the brain of adrenomyeloneuropathy subjects in the early stages of th

28 In adrenomyeloneuropathy the spinal cord is the main site o

29 Ambulatory men aged 18-65 years with adrenomyeloneuropathy without gadolinium enhancing lesio